Latest Health stories from Life.
Spanish authorities are set to receive over 140 passengers and crew from a cruise ship affected by hantavirus as it approaches the Canary Islands.
Roche has reached an agreement to purchase PathAI for $750 million, aiming to enhance the application of artificial intelligence in disease diagnosis by pathologists.
The potential dismissal of FDA Commissioner Makary could lead to another significant vacancy within RFK Jr.'s health department, raising questions about future leadership.
Capricor Therapeutics has raised concerns about Nippon Shinyaku and its U.S. branch regarding the implementation of a treatment for Duchenne muscular dystrophy.
The rise of hantavirus misinformation highlights ongoing challenges in public health communication. This week, I received alerts from followers about misleading claims.
As discussions around mifepristone continue, former FDA leaders and pharmaceutical representatives raise critical questions about regulatory authority.
The pharmaceutical industry is experiencing notable shifts with various new hires, departures, and promotions. Here’s a summary of the latest changes.
The recent Met Gala sparked speculation about the influence of biotech logos on celebrity fashion choices. Did Naomi Osaka and Janelle Monáe draw inspiration from Gilead and Insilico? Likely not.
Today's biotech news highlights a lawsuit concerning Duchenne therapy and challenges faced by FDA Commissioner Marty Makary in relation to the White House.
The FDA's recent proposal to remove 'gender' from its regulations has raised concerns about potential impacts on research outcomes and unintended consequences.
This brief outlines the GENEROUS model and explores various elements that may influence Medicaid drug costs, emphasizing the importance of confidentiality regarding certain model details.
While Medicare's new RAPID pathway represents significant progress for adult patients, the pediatric device pipeline remains critically underfunded and slow, raising concerns for children's healthcare.
With men constituting only 12% of the nursing workforce in the U.S., there is a pressing need to encourage more men to enter this vital profession.
This week's STATus Report features six former FDA officials discussing their reasons for leaving the agency, shedding light on their experiences.
A recent study reveals an increase in fabricated citations in research papers, attributed to AI hallucinations, raising concerns about the integrity of scientific literature.
In this week's episode of "The Readout LOUD" podcast, we delve into Seaport Therapeutics' IPO success, the competitive landscape of obesity treatments, and the challenges faced by the FDA commissioner.
Recent developments suggest that a political appointee may be obstructing the approval process for a Sanofi drug, raising alarms about potential political interference at the FDA.
Sanofi has requested the FDA to withdraw teplizumab from its fast-track review program following internal disagreements regarding the drug's approval.
The FDA is revisiting a rare cancer treatment it had turned down earlier this year, amidst discussions on drug pricing and advancements in biotech.
OpenAI has released a health policy blueprint while Dexcom updates its continuous glucose monitoring technology, alongside concerns regarding whole body scans.